ArticleComputational and structural biotechnology journal2025
MTIOT: Identifying HPV subtypes from multiple infection data.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Microbiome-Metabolome Crosstalk in HPV Pathogenesis: From Ecosystem Dynamics to Translational Biomarkers.Computational and structural biotechnology journal · 2026Review
- Systems Analysis of miRNA-Mediated Host Regulatory Response in HPV-Associated Cervical Malignancy.Computational and structural biotechnology journal · 2026Article
- Unraveling the mechanisms of LncRNAs in cervical cancer: a comprehensive review.Cell death discovery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with high-risk human papillomavirus (hrHPV) is a major cause of cervical cancer. The effectiveness of current HPV-DNA testing, which is crucial for early detection, is limited in several aspects, including low sensitivity, accuracy issues, and the inability to perform comprehensive hrHPV typing. To address these limitations, we introduce MTIOT (Multiple subTypes In One Time), a novel detection method that utilizes machine learning with a new multichannel integration scheme to enhance HPV-DNA analysis. This approach may enable more accurate and rapid identification of multiple hrHPV types within a single sample. Compared to traditional methods, MTIOT has the potential to overcome their core limitations and offer a more efficient and cost-effective solution for cervical cancer screening. When tested on both simulated samples (to mimic real-world complexities) and clinical samples, MTIOT achieved F1 scores (the harmonic mean of sensitivity and specificity) of 98 % and 92 % respectively for identifying subtypes with a sample size ≥ 50, suggesting that it may significantly improve the precision of cervical cancer screening programs. This work with MTIOT represents a significant step forward in the molecular diagnosis of hrHPV and may suggest a promising avenue for enhancing early detection strategies and potentially reducing the incidence of cervical cancer. This study also underscores the importance of methodological innovation in tackling public health challenges and sets the stage for future clinical trials to validate MTIOT's efficacy in practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.